WO2008153374A8 - Composición farmacéutica que comprende la combinación de un agente inhibidor de la enzima hmg-coa reductasa y un agente inhibidor de la enzima lipasa gastrointestinal - Google Patents

Composición farmacéutica que comprende la combinación de un agente inhibidor de la enzima hmg-coa reductasa y un agente inhibidor de la enzima lipasa gastrointestinal Download PDF

Info

Publication number
WO2008153374A8
WO2008153374A8 PCT/MX2008/000077 MX2008000077W WO2008153374A8 WO 2008153374 A8 WO2008153374 A8 WO 2008153374A8 MX 2008000077 W MX2008000077 W MX 2008000077W WO 2008153374 A8 WO2008153374 A8 WO 2008153374A8
Authority
WO
WIPO (PCT)
Prior art keywords
inhibiting agent
enzyme
pharmaceutical composition
coa reductase
gastrointestinal lipase
Prior art date
Application number
PCT/MX2008/000077
Other languages
English (en)
French (fr)
Other versions
WO2008153374A1 (es
Inventor
María Elena GARCÍA ARMENTA
Josefina Santos Murillo
Víctor Guillermo ALVAREZ OCHOA
Original Assignee
ESPINOSA ABDALA, Leopoldo de Jesús
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ESPINOSA ABDALA, Leopoldo de Jesús filed Critical ESPINOSA ABDALA, Leopoldo de Jesús
Priority to PL08778967T priority Critical patent/PL2179732T3/pl
Priority to BRPI0813174-0A2A priority patent/BRPI0813174A2/pt
Priority to ES08778967.3T priority patent/ES2492665T3/es
Priority to EP08778967.3A priority patent/EP2179732B1/en
Publication of WO2008153374A1 publication Critical patent/WO2008153374A1/es
Publication of WO2008153374A8 publication Critical patent/WO2008153374A8/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención esta relacionada con una composición farmacéutica compuesta por la combinación sinérgica de un agente inhibidor de la enzima HMG-CoA reductasa, como lo es el principio activo: Atorvastatina y un agente inhibidor de la enzima lipasa gastrointestinal, como lo es el principio activo: Orlistat, los cuales se encuentran formulados en una sola unidad de dosificación para ser administrada por vía oral, misma que está indicada para el tratamiento y control de enfermedades tales como: dislipidemias (hipercolesterolemia e hipertrigliceridemia) y otras patologías relacionadas.
PCT/MX2008/000077 2007-06-15 2008-06-16 Composición farmacéutica que comprende la combinación de un agente inhibidor de la enzima hmg-coa reductasa y un agente inhibidor de la enzima lipasa gastrointestinal WO2008153374A1 (es)

Priority Applications (4)

Application Number Priority Date Filing Date Title
PL08778967T PL2179732T3 (pl) 2007-06-15 2008-06-16 Kompozycja farmaceutyczna łącząca środek hamujący enzym reduktazę HMG-CoA i środek hamujący enzymy lipazy żołądkowo-jelitowe
BRPI0813174-0A2A BRPI0813174A2 (pt) 2007-06-15 2008-06-16 Composição farmacêutica que compreende a combinação de um agente inibidor da enzima hmg-coa redutase e um agente inibidor da enzima lipase gastrointestinal
ES08778967.3T ES2492665T3 (es) 2007-06-15 2008-06-16 Composición farmacéutica que comprende la combinación de un agente inhibidor de la enzima HMG-CoA reductasa y un agente inhibidor de la enzima lipasa gastrointestinal
EP08778967.3A EP2179732B1 (en) 2007-06-15 2008-06-16 Pharmaceutical composition combining an enzyme hmg-coa reductase inhibiting agent and a gastrointestinal lipase enzyme inhibiting agent

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
MX2007007283A MX2007007283A (es) 2007-06-15 2007-06-15 Composicion farmaceutica que comprende la combinacion de un agente inhibidor de la enzima hmg-coa reductasa y un agente inhibidor de la enzima lipasa gastrointestinal.
MXMX/A/2007/007283 2007-06-15

Publications (2)

Publication Number Publication Date
WO2008153374A1 WO2008153374A1 (es) 2008-12-18
WO2008153374A8 true WO2008153374A8 (es) 2010-02-04

Family

ID=40129898

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/MX2008/000077 WO2008153374A1 (es) 2007-06-15 2008-06-16 Composición farmacéutica que comprende la combinación de un agente inhibidor de la enzima hmg-coa reductasa y un agente inhibidor de la enzima lipasa gastrointestinal

Country Status (11)

Country Link
EP (1) EP2179732B1 (es)
AR (1) AR067038A1 (es)
BR (1) BRPI0813174A2 (es)
CO (1) CO6241106A2 (es)
CY (1) CY1115453T1 (es)
EC (1) ECSP099801A (es)
ES (1) ES2492665T3 (es)
GT (1) GT200900316A (es)
MX (1) MX2007007283A (es)
PL (1) PL2179732T3 (es)
WO (1) WO2008153374A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110314232A (zh) * 2019-08-03 2019-10-11 黄泳华 由脂肪酶抑制剂与羟甲戊二酰辅酶a还原酶抑制剂构成的组合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060148721A1 (en) * 2003-06-06 2006-07-06 Erondu Ngozi E Combination therapy for the treatment of dyslipidemia
WO2006109170A2 (en) * 2005-04-14 2006-10-19 Esperion Therapeutics Inc. Combination therapy for treatment of cardiovascular diseases and related conditions
MXPA06010973A (es) * 2006-09-25 2009-02-18 World Trade Imp Export Wtie Ag Composicion farmaceutica para el tratamiento del sobrepeso y la obesidad que se acompañan la dislipidemia.

Also Published As

Publication number Publication date
EP2179732A4 (en) 2010-08-25
MX2007007283A (es) 2009-02-18
ECSP099801A (es) 2010-01-29
AR067038A1 (es) 2009-09-30
ES2492665T3 (es) 2014-09-10
PL2179732T3 (pl) 2014-10-31
EP2179732A1 (en) 2010-04-28
GT200900316A (es) 2011-07-25
WO2008153374A1 (es) 2008-12-18
BRPI0813174A2 (pt) 2014-12-23
EP2179732B1 (en) 2014-05-14
CY1115453T1 (el) 2017-01-04
CO6241106A2 (es) 2011-01-20

Similar Documents

Publication Publication Date Title
WO2007128086A3 (en) Novel viral replication inhibitor
WO2007097931A3 (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2007136603A3 (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2006096439A3 (en) Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
WO2005046575A3 (en) Amino acid prodrugs
IL193252A0 (en) N-hydroxyacrylamide compounds
WO2007100614A3 (en) STABLE NON-CRYSTALLINE FORMULATION COMPRISING HMG-CoA REDUCTASE INHIBITOR
WO2007138466A3 (en) Pharmaceutical compositions comprising meloxicam and tramadol combination
WO2008073138A3 (en) Terephthalamate compounds and compositions, and their use as hiv integrase inhibitors
WO2007102888A3 (en) Methods of treating cancer with doxazolidine and prodrugs thereof
WO2008054808A3 (en) Elvucitabine pharmaceutical compositions
WO2009041787A3 (en) Pharmaceutical composition comprising inhibitors of cell adhesion molecule isolated from piper nigrum for the prevention and treatment of inflammatory disease
WO2008001201A3 (en) Pharmaceutical compositions of clopidogrel
EA201401042A1 (ru) ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И КОМБИНИРОВАННОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, СОДЕРЖАЩЕЕ ИНГИБИТОРЫ HMG-CoA-РЕДУКТАЗЫ И ФОСФОДИЭСТЕРАЗЫ 4, И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ВОСПАЛИТЕЛЬНЫХ ЗАБОЛЕВАНИЙ ЛЕГКИХ
WO2007110834A3 (en) Malate salts, and polymorphs of (3s,5s)-7-[3-amino-5-methyl-piperidinyl]-1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid
WO2010062506A3 (en) Decahydro-1h-indenoquinolinone and decahydro-3h-cyclopentaphenanthridinone cyp17 inhibitors
WO2006117761A3 (en) Magnesium salts of hmg-coa reductase inhibitors
WO2007081808A3 (en) Compounds and derivatives for the treatment of medical conditions by modulating hormone-sensitive lipase activity
WO2008081268A3 (en) Pharmaceutical compositions of entacapone
GR1006879B (el) Βελτιωμενες φαρμακευτικες συνθεσεις που περιεχουν αναστολεις της αναγωγασης του 3-υδροξυ-3-μεθυλογλουταρυλοσυνενζυμου α (hmg-coa) και μεθοδος παρασκευης αυτων
WO2008020314A3 (en) Statin stabilizing dosage formulations
WO2009041786A3 (en) Pharmaceutical composition comprising inhibitors of cell adhesion molecule isolated from piper longum for the prevention and treatment of inflammatory disease
WO2009015446A3 (en) Triazole derivatives as viral replication inhibitors
WO2004071402A3 (en) STABLE PHARMACEUTICAL DOSAGE FORM COMPRISING HMG-CoA REDUCTASE INHIBITOR
WO2011103920A3 (en) Pharmaceutical or neutraceutical formulation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08778967

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 09141944

Country of ref document: CO

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008778967

Country of ref document: EP

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
ENP Entry into the national phase

Ref document number: PI0813174

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20091215